ARTICLE | Company News
Bird Rock, J&J deal
January 6, 2017 10:31 PM UTC
The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson partnered with Bird Rock to develop the biotech's namacizumab. The antibody targets cannabinoid CB1 receptor (CNR1) and is in Phase I testing...
BCIQ Target Profiles